The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

The study has more than one part. In the first part, small groups of people receive the drug combinations so that researchers can watch for side effects and choose a dose that can be used more widely. In the later part, more people receive the combinations to learn more about how the treatment works in the different cancer groups and to compare dose options in some groups. Because this is an open-label trial, everyone knows which treatment is being given.

During the trial, the treatment is given over time, and participants are followed closely while they are receiving it and for a period afterward. Doctors check for side effects, how well the cancer seems to respond, and how the body handles the drugs. The study includes people with several cancer types, and the treatment plan may differ depending on the cancer group and the study part.

The purpose of the study is to evaluate PFS at 12 months compared with historical results. After the first infusion, patients return for regular treatment sessions over several months while doctors monitor the cancer for any signs of growth or spread, record any side effects that are related to the immune system, and assess overall well‑being. PFS means the length of time a person lives without the disease getting worse. Immune‑related side effects are reactions that happen because the treatment activates the body’s own defenses, and quality of life refers to how a person feels and functions during the study.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

The purpose of this study is to evaluate how well cemiplimab works when given before and after standard chemoradiotherapy in patients with locally advanced cervical carcinoma by measuring how many patients respond to the treatment. During the study, patients will first receive cemiplimab treatment, then undergo the standard chemoradiotherapy with cisplatin and radiation, and finally continue with cemiplimab treatment for a maintenance period. The cemiplimab will be given through an infusion into a vein, which means the medication is delivered directly into the bloodstream through a needle placed in a vein. The cisplatin will also be given through infusion into a vein during the chemoradiotherapy phase.

The study will measure whether the cancer shrinks or disappears completely after treatment, how long patients live without the cancer getting worse, and overall survival. It will also examine how the treatment affects quality of life and will monitor for any side effects that may occur during treatment. Additionally, the study will collect tissue samples to look at biological markers that might help predict which patients will respond best to the treatment. Patients will be followed for several years to assess the long-term effectiveness of this treatment approach.

Women in this study will first receive standard treatment for their cancer, which includes chemoradiation, a combination of chemotherapy and radiation therapy, along with brachytherapy, a type of internal radiation treatment where the radiation source is placed directly inside or very close to the cancer. During this standard treatment, participants will also begin receiving Keytruda through an intravenous infusion, which means the medication is given directly into a vein. After completing the radiation treatments, there will be an eight-week waiting period to allow the body to recover.

Following the eight-week recovery period, participants will continue receiving Keytruda infusions and will also start taking Lenvatinib capsules by mouth, which means the medication is taken orally. Treatment with Keytruda can continue for up to 24 months, while Lenvatinib can be given for up to 12 months. Throughout the study, doctors will monitor how well the cancer responds to treatment and whether it grows or spreads. The study will track participants to measure the time period during which the cancer does not get worse, which doctors call progression free survival.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The purpose of the study is to compare different combinations of these medications to see which treatment works better at keeping the cancer from getting worse and helping people live longer. The study will also look at how safe these treatments are and how they affect quality of life. The study has two parts. The first part is a safety check with a small number of people to make sure the combination of sacituzumab tirumotecan, pembrolizumab, and bevacizumab is safe to use together. The second part will compare different treatment combinations to standard treatments.

Participants will receive their assigned treatment as maintenance therapy, which means treatment given after initial therapy to help keep the cancer under control. During the study, doctors will regularly check how the cancer is responding to treatment using imaging scans and will monitor for any side effects. Participants will also be asked questions about their daily activities and how they are feeling to understand how the treatment affects their quality of life. The study will track whether the cancer grows or spreads and how long participants live.

Participants in the study will receive the Gardasil 9 vaccine, which is given as an injection. The study will monitor how many women receive the vaccine and how well they follow the vaccination schedule. The goal is to see if this combined approach of vaccination and screening can reduce the number of HPV infections and, ultimately, cases of cervical cancer in the population.

The study will take place over several years, with the aim of understanding the long-term benefits of this approach. By focusing on young women who are due for cervical cancer screening, the study hopes to provide valuable insights into the effectiveness of combining vaccination with regular health checks in preventing HPV-related diseases.

The trial will involve several treatments, including estriol, estradiol hemihydrate, promestriene, progesterone, and estradiol valerate. Estriol is administered as a vaginal treatment, while estradiol hemihydrate is given through a transdermal patch, which means it is absorbed through the skin. Promestriene is used as a vaginal cream, progesterone is taken orally in the form of soft capsules, and estradiol valerate is provided as coated tablets for oral use. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

Participants in the study will be monitored over a period of time to assess changes in their sexual function and quality of life. This will include completing forms like the Female Sexual Function Index (FSFI) and quality of life questionnaires at different stages: before treatment, shortly after treatment, and at six and twelve months post-treatment. The study aims to gather information on how these treatments affect various aspects of sexual health, such as desire, lubrication, orgasm, satisfaction, and any pain or discomfort experienced. Additionally, the study will evaluate the overall health and well-being of participants, including physical, emotional, and social functioning, as well as any side effects from the treatments.

The purpose of the study is to assess how well Raludotatug Deruxtecan works in treating these cancers and to monitor any side effects. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period to observe the treatment’s impact on their cancer and overall health.

Throughout the trial, researchers will focus on understanding how the treatment affects the size and growth of the tumors, as well as any changes in the participants’ health. The study aims to provide valuable information on the potential benefits and risks of using Raludotatug Deruxtecan for these types of cancers, contributing to future treatment options for patients with advanced or metastatic solid tumors.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The purpose of this study is to find the best dose of Fianlimab and the best time to perform a special type of imaging called PET scan to see how the treatment is working. A PET scan is a test that helps doctors see how organs and tissues inside the body are functioning. The study will also look at how safe Fianlimab is for patients. Participants will receive the treatment and undergo PET scans before and during their treatment with Cemiplimab, with or without chemotherapy. The study will help researchers understand how the treatment affects the body and how well it works against the cancer.

Throughout the study, patients will be monitored closely to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information that could lead to better treatment options for people with advanced solid cancers. By understanding how these medications work together, researchers hope to improve outcomes for patients facing these challenging diseases.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to see if using ANV419 can reduce certain side effects that are commonly associated with IL-2 treatment. The study will also look at how these treatments affect patients’ quality of life and their own reports of symptoms. Participants will receive either the new drug ANV419 or high-dose IL-2 after their TIL therapy. The study will monitor the patients for any side effects and changes in their condition over time.

Throughout the study, patients will undergo regular assessments to track their response to the treatment and any changes in their health. The trial aims to provide valuable information on the effectiveness and safety of using ANV419 compared to high-dose IL-2 in treating these types of cancer. This research could lead to improved treatment options for patients with advanced melanoma, NSCLC, and cervical cancer.

The purpose of this study is to evaluate how safe and effective these drug combinations are for treating these types of cancer. The study is divided into two parts – first checking the safety of the treatment combinations, and then examining how well they work in fighting the cancer.

During the study, participants will receive their assigned treatment combination through intravenous infusion. The treatments will be given in cycles, and patients will be monitored regularly to check their response to the treatment. Doctors will use imaging scans to measure if tumors are shrinking and will track any side effects that may occur. The total treatment period may last up to 24 months, depending on how well patients respond to the treatment.

The purpose of the study is to evaluate the safety and effectiveness of Tolinapant in treating these advanced cancers. Participants in the study will receive the medication in the form of a capsule taken by mouth. The study will be conducted in phases, with the first phase already completed. The second phase will focus on assessing how well the medication works in reducing the size of tumors or slowing their growth. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Tolinapant.

Throughout the study, participants will be monitored for any side effects and changes in their condition. The study aims to determine the best dose of Tolinapant and to gather information on how the body processes the medication. This information will help researchers understand the potential benefits and risks of using Tolinapant as a treatment for advanced cancers. The study is expected to continue until the end of 2025.

The purpose of the study is to evaluate the benefits of adding atezolizumab to the standard treatment for cervical cancer. Participants in the study will be randomly assigned to receive either the standard chemoradiotherapy alone or chemoradiotherapy with atezolizumab. The study will monitor how well the cancer responds to the treatment and how long patients remain free from cancer progression. The study will also look at overall survival rates and any side effects that may occur during and after the treatment.

Throughout the study, participants will receive regular assessments to track the progress of their cancer and any potential side effects. These assessments will include imaging tests like MRI to measure the size of the cancer and determine if it is responding to the treatment. The study aims to provide valuable information on whether adding atezolizumab to the standard treatment can offer better outcomes for patients with locally advanced cervical cancer.

Volrustomig, also known by its code name MEDI5752, is a type of medication called a monoclonal antibody. It is designed to target specific proteins in the body that may help the immune system fight cancer cells. In this study, volrustomig will be compared to a placebo to see if it can improve outcomes for patients. The study will also involve other medications such as Mycofit and Remsima, which are used in different contexts within the trial. Mycofit contains the active substance mycophenolate mofetil, and Remsima contains infliximab.

Participants in the trial will receive either volrustomig or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants over time to assess the progression of the cancer and overall survival rates. The goal is to see if volrustomig can help delay the progression of the disease and improve the quality of life for those affected by locally advanced cervical cancer. The trial is expected to continue until 2029, with recruitment starting in 2024.

Participants in this study will receive dostarlimab as a maintenance therapy, which means it is used to help keep the cancer under control after the initial treatment. The study will compare the effects of dostarlimab with those of a placebo to understand how well it works in maintaining the health of patients with high-risk locally advanced cervical cancer. The study will monitor patients over a period of time to see how long they remain free from cancer progression and to assess their overall survival and quality of life.

Throughout the study, patients will be regularly checked to see how they are responding to the treatment and to ensure their safety. The study aims to provide valuable information on whether dostarlimab can be an effective option for patients with this type of cervical cancer, potentially offering a new way to manage the disease after initial treatments have been completed.

Before receiving LN-145, patients will be given three preparatory medications: cyclophosphamide, fludarabine phosphate, and aldesleukin. These medications are administered through intravenous infusion to prepare the body for the cell therapy treatment. The study includes different groups of patients, including those who have previously received other cancer treatments and those who haven’t.

The main purpose of this study is to determine if LN-145 is effective and safe for treating cervical cancer that has spread or returned after previous treatments. The treatment process involves removing tumor tissue through surgery, processing the tissue in a laboratory to obtain the tumor-fighting cells, and then giving these cells back to the patient through an intravenous infusion.

The purpose of the study is to determine the best dose of tisotumab vedotin when used in combination with other treatments and to evaluate its effectiveness in treating cervical cancer. The study will begin with a phase called dose escalation, where different doses of the medication are tested to find the highest dose that can be given safely. After this, the study will move to a phase called dose expansion, where the focus will be on understanding how well the medication works in treating the cancer.

Participants in the study will receive the medication as a solution for infusion, which means it will be given through a vein. The study will monitor the safety of the treatments and any side effects that may occur. The trial aims to provide valuable information about the potential benefits and risks of using tisotumab vedotin, alone or in combination, for treating advanced cervical cancer.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The purpose of the study is to determine if adding pembrolizumab to chemoradiotherapy improves outcomes for patients with high-risk, locally advanced cervical cancer. Participants in the study will be randomly assigned to receive either the combination of pembrolizumab and chemoradiotherapy or chemoradiotherapy with a placebo. The study will monitor participants over a period to assess how well the cancer responds to the treatment and to evaluate overall survival rates.

Throughout the study, participants will receive their assigned treatments through intravenous infusion, which means the medication is given directly into a vein. The study aims to provide valuable information on whether pembrolizumab can enhance the effectiveness of standard chemoradiotherapy in treating this type of cervical cancer. Participants will be closely monitored by healthcare professionals to ensure their safety and to track the progress of their treatment.

Participants in the study will first receive three cycles of the medications Paclitaxel and Carboplatin. After this initial phase, they will continue with the standard treatment, which involves a combination of chemotherapy and radiation therapy given at the same time. This approach is known as concurrent chemoradiotherapy. The study will compare the outcomes of patients who receive this additional initial treatment with those who only receive the standard treatment.

The trial aims to assess various outcomes, including overall survival, which is the time from the start of the study until death from any cause. It will also look at how well the tumor responds to the treatment, the time until the cancer progresses or returns, and the quality of life of the participants. Additionally, the study will monitor any side effects that occur during the treatment. The trial is expected to continue until January 2028.

The purpose of the study is to evaluate whether receiving the HPV 9-valent vaccine before surgery can help reduce the chances of the disease coming back after surgery. Participants in the study will receive either the vaccine or a placebo. The study will follow participants over a period of time to see if the vaccine helps in reducing the recurrence of the disease and in managing infections that might occur after surgery.

Participants will be monitored for changes in their health, including the presence of HPV infections and the results of tests like the Pap test, which checks for changes in the cells of the cervix. The study aims to provide valuable information on the effectiveness of the vaccine in preventing the recurrence of cervical disease after surgical treatment.

The purpose of the study is to assess the safety and tolerability of AZD9574 in patients with these advanced cancers. Participants will receive the medication in the form of a film-coated tablet taken orally. The study will monitor how the body processes the drug, its effects on the cancer, and any side effects that may occur. Some participants may receive a placebo for comparison. The study will also explore how the drug affects specific biomarkers, which are indicators of how the body is responding to the treatment.

Throughout the study, participants will undergo regular health checks, including blood tests and imaging scans, to track their progress and the impact of the treatment. The study aims to gather information over a period of time to determine the potential benefits and risks of AZD9574 for treating these types of cancers. This research is important for developing new treatment options for patients with advanced solid tumors.

The purpose of the study is to evaluate how safe and effective these treatments are when used together in patients with advanced stages of these HPV-16 related cancers. The study will be conducted in two phases. In the first phase, the focus will be on understanding the safety and how well patients tolerate the combination of avelumab and TG4001. In the second phase, the study will look at how well the combination works in terms of slowing down the progression of the cancer compared to using avelumab alone.

Participants in the study will receive the treatments through injections or infusions, and their health will be monitored over time to see how the cancer responds to the treatment. The study aims to provide valuable information on whether this combination of treatments can offer a new option for patients with these types of cancers.

The purpose of the study is to see if it is possible to preserve fertility in women with this type of cervical cancer by using the combination of chemotherapy and surgery, without needing additional treatments afterward. Participants in the study will receive up to three cycles of chemotherapy over a period of up to 12 weeks. After the chemotherapy, if the tumor has shrunk to a certain size, the participants will undergo the fertility-sparing surgery. The study will monitor the participants to determine the success of the treatment in preserving fertility.

This trial is designed to help understand if this treatment approach can be a viable option for women who wish to maintain their ability to have children in the future while effectively treating their cervical cancer. The study will continue to gather information until the end of 2035, providing valuable insights into the effectiveness and safety of this treatment strategy.

Participants in the study will receive either Tisotumab Vedotin or one of the chemotherapy drugs, which may include Vinorelbine, Topotecan, Irinotecan, Pemetrexed, or Gemcitabine. These medications are given through an infusion, which means they are delivered directly into the bloodstream through a vein. The study will also involve the use of eye drops, such as Brimonidine Tartrate and Dexamethasone, which are used for different purposes related to eye health. The trial will monitor the overall survival of participants, which means the length of time they live after starting the treatment, as well as other factors like how long the cancer stays under control and any side effects experienced.

The study is designed to help researchers understand if Tisotumab Vedotin can provide better outcomes for patients with recurrent or metastatic cervical cancer compared to the standard chemotherapy options. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather important information about the effectiveness of the treatments being tested. The trial aims to provide valuable insights that could lead to improved treatment options for patients with this challenging condition.

Participants in the study will receive the treatment over a period of up to 24 months. The treatment involves administering the medications through an intravenous infusion, which means they are given directly into the bloodstream through a vein. Throughout the study, participants will be monitored for any side effects and to see how well the treatment is working. This includes regular check-ups, blood tests, and other assessments to ensure the safety and effectiveness of the treatment.

The study will also involve a comparison with a placebo to better understand the effects of the treatment. The main focus will be on the safety of the treatment, looking at any side effects that occur, and its effectiveness, such as whether the cancer shrinks or stops growing. The study aims to provide valuable information that could lead to new treatment options for these types of cancer in the future.

The purpose of the study is to determine if adding additional treatment with chemotherapy and radiation after surgery can help patients live longer without the cancer coming back. Participants in the study will be randomly assigned to one of two groups. One group will receive the additional treatment with chemotherapy and radiation after surgery, while the other group will not receive any further treatment after surgery. The study will follow participants over a period of time to see how well they do with each approach.

Throughout the study, participants will receive regular check-ups and monitoring to assess their health and the status of their cancer. The study aims to provide valuable information on the best treatment approach for patients with this type of cervical cancer, potentially improving outcomes and quality of life for those affected by the disease.

The purpose of the study is to find out if adding atezolizumab to the usual treatment of chemotherapy and bevacizumab can improve the time patients live without their cancer getting worse and if it can help them live longer overall. Participants in the study will be randomly assigned to receive either the combination of paclitaxel, bevacizumab, and atezolizumab or just paclitaxel and bevacizumab. The study will last for a period of time, and participants will receive regular infusions of the drugs. Some participants may receive a placebo instead of atezolizumab to compare the effects of the treatment.

Throughout the study, participants will be monitored closely by healthcare professionals to track their progress and any side effects they may experience. The study aims to provide valuable information on whether the addition of atezolizumab can offer better outcomes for patients with metastatic, persistent, or recurrent cervical cancer. This research could potentially lead to new treatment options for this type of cancer in the future.